Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation (Phase 4)
2016-002353-38Phase 4Active
- Sponsor
- University of Ottawa Heart Institute
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of rivaroxaban in Atrial fibrillation (AFib), stroke and cerebral embolism (2 arms), sponsored by University of Ottawa Heart Institute. Primary endpoint: Composite of stroke, systemic embolism, and covert embolic stroke. Started Nov 2016; status: active.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)strokecerebral embolism
Beyond the preview
Go deeper on 2016-002353-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002353-38.